Résumé
La prise en charge de l’adénocarcinome pancréatique est un enjeu majeur. En effet, malgré les progrès de la chirurgie et de la chimiothérapie, son pronostic reste sombre. Les essais thérapeutiques de phase III évaluant des thérapies ciblées ont été jusqu’à présent des échecs, peut-être en raison de la sélection des patients sur des facteurs prédictifs d’efficacité. Des analyses systématiques du génome tumoral pour le développement d’un traitement personnalisé en maintenance après réponse à un traitement d’induction pourraient être plus concluantes. Enfin, les résultats préliminaires publiés et les essais thérapeutiques à venir permettront, au travers de collaborations transversales, de faire avancer nos connaissances.
Abstract
The treatment of pancreatic adenocarcinoma is a major challenge. Despite progress, both in terms of surgical techniques and chemotherapy, prognosis remains unfavourable. Targeted therapies have failed in all phase III studies, which may be due to the absence of selecting patients on factors to predict efficacy. The systematic analyses of the tumour genome for the development of a personalised treatment would be one option. The preliminary results published and therapeutic trials to come will allow advancements in our knowledge to be made, through cross-discipline collaborations.
Références
Conroy T, Desseigne F, Ychou M, et al. (2011) Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–25
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65: 5–29
Von Hoff DD, Ervin T, Arena FP, et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691–703
Cao Y, Wu L, Tan A, et al. (2010) Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer. Pancreas 39: 253–5
Rahib L, Smith BD, Aizenberg R, et al. (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913–21
Biankin AV, Waddell N, Kassahn KS, et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399–405
Jones S, Zhang X, Parsons DW, et al. (2008) Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–6
Waddell N, Pajic M, Patch AM, et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518: 495–501
Witkiewicz AK, McMillan EA, Balaji U, et al. (2015) Whole exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6: 6744
Kindler HL, Niedzwiecki D, Hollis D, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617–22
Philip PA, Benedetti J, Corless CL, et al. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605–10
van Cutsem E, van de Velde H, Karasek P, et al. (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430–8
Gonçalves A, Gilabert M, François E, et al. (2012) BAYPAN study: a double blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 23: 2799–805
Bodoky G, Timcheva C, Spigel DR, et al. (2012) A phase II openlabel randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30: 1216–23
Infante JR, Somer BG, Park JO, et al. (2014) A randomised, double blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 50: 2072–81
Chantrill LA, Nagrial AM, Watson C, et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res 21: 2029–37
Von Hoff DD, Stephenson JJ, Rosen P, et al. (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28: 4877–83
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
de la Fouchardière, C., Dahan, L. Cancers du pancréas : articulation entre la recherche fondamentale et la recherche clinique. Oncologie 17, 541–544 (2015). https://doi.org/10.1007/s10269-015-2570-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-015-2570-8